Digestive System Diseases: Clinical Trials

47 trials for Digestive System Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

47 suspended. 47 Phase 2, 16 Phase 1, 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 247Suspended 47
Phase 116Suspended 16
Phase 35Suspended 5

Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases

Trials (filtered) newest first · largest first

All 47 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer
CA102N, TAS-102, Bevacizumab - Metastatic Colorectal Cancer
Phase 2SuspendedHoly Stone Healthcare Co., Ltd1002027-12-012026-09-18
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
Rintatolimod - Pancreatic Cancer
Phase 2SuspendedAIM ImmunoTech Inc.902027-08-012026-08-19
CLF065 for Chronic Pouchitis
CLF065, Placebo - Pouchitis
Phase 2SuspendedCalibr, a division of Scripps Research202026-06-012026-07-09
TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer
TGFBR2 KO CAR27/IL-15 NK cells - Pancreatic Cancer
Phase 1 / Phase 2SuspendedM.D. Anderson Cancer Center372026-05-262026-11-03
Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites
Stereotactic body radiation therapy (SBRT), Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.) - Metastatic Colorectal Cancer, Oligometastatic Disease
Phase 2SuspendedUMC Utrecht932025-12-012025-03-28
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Trifluridine/tipiracil, Oxaliplatin - Biliary Tract Cancer, Biliary Tract Neoplasms
Phase 2SuspendedCase Comprehensive Cancer Center272025-12-012026-10-20
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
Systemic therapy, Radiotherapy - Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Phase 2SuspendedShandong Cancer Hospital and Institute1842025-11-302026-10-15
HEARTS Trial for Thoracic Cancers
MRgART, LINAC - Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III
Phase 2SuspendedUniversity of Wisconsin, Madison602025-10-082026-10-30
Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma
Adebrelimab - Adebrelimab, Hepatocellular Carcinoma
Phase 2SuspendedTianjin Medical University Cancer Institute and Hospital402024-05-012026-05-29
Endorectal Brachytherapy for Rectal Cancer
Endorectal brachytherapy - Locally Advanced Rectal Carcinoma
Phase 2SuspendedUniversity Hospital, Bordeaux312024-01-312025-08-01
Immunotherapy for Advanced Liver Cancer
AlloStim® immunotherapy, FOLFOX regimen, Sorafenib - Hepatocellular Carcinoma
Phase 2 / Phase 3SuspendedMirror Biologics, Inc.1502023-08-012025-10-23
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule - Stage II Colon Cancer, Stage III Colon Cancer
Phase 2SuspendedGruppo Oncologico del Nord-Ovest4772023-05-172026-02-03
Switch Maintenance in Pancreatic
ZIMBERELIMAB, DOMVANALIMAB, APX005M - Pancreatic Cancer, Adenocarcinoma of the Pancreas
Phase 1 / Phase 2SuspendedJames Cleary, MD, PhD462022-11-302026-06-04
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
VS-6766/avutometinib, Cetuximab, Pill Diary - Colorectal Cancer, Colorectal Adenocarcinoma
Phase 1 / Phase 2SuspendedUniversity of Chicago532022-08-222026-05-08
A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer
camrelizumab+chemotherapy, Chemotherapy - Gastric Cancer
Phase 1 / Phase 2SuspendedShanghai Minimally Invasive Surgery Center1002022-07-012024-03-07
Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer
combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) - Cancer of Rectum
Phase 2SuspendedRutgers, The State University of New Jersey382022-05-132025-12-04
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
ChAdOx1-MAGEA3-NYESO (Route = IM injection, Dose = 5×10^10 vp), MVA-MAGEA3 (Route = IM injection, Dose = 1.3×10^8 pfu), Standard of care treatment - Non-small Cell Lung Cancer (NSCLC), Squamous Oesophageal Cancer
Phase 1 / Phase 2SuspendedCancer Research UK152021-10-152026-04-06
A Study of ABTL0812 in Pancreatic Cancer
ABTL0812, Gemcitabine and nab-paclitaxel - Pancreatic Cancer
Phase 1 / Phase 2SuspendedAbility Pharmaceuticals SL602021-04-262025-10-01
EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden
Liver-resection or ablation, 2nd line chemotherapy - Liver Metastases, Colorectal Cancer
Phase 2SuspendedOslo University Hospital622021-03-232026-10-22
Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics
Somatostatin analog - Pancreatic Diseases
Phase 2 / Phase 3SuspendedMayo Clinic1032020-11-172026-04-03

Showing 20 of 47. Sign in to see all of them.

Narrower conditions

Pancreatic Neoplasms (11)  ·  Colorectal Neoplasms (9)  ·  Stomach Neoplasms (7)  ·  Carcinoma, Hepatocellular (5)  ·  Neoplasms (4)  ·  Rectal Neoplasms (4)  ·  Colonic Neoplasms (3)  ·  Esophageal Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Lung Neoplasms (2)  ·  Neoplasm Metastasis (2)  ·  Peritoneal Neoplasms (2)  ·  Abdominal Pain (1)  ·  Adenocarcinoma (1)  ·  Adenocarcinoma Of Esophagus (1)

Broader conditions

Digestive System Neoplasms (40)  ·  Neoplasms by Site (40)  ·  Neoplasms (36)  ·  Gastrointestinal Diseases (28)  ·  Gastrointestinal Neoplasms (23)  ·  Intestinal Diseases (19)  ·  Intestinal Neoplasms (15)  ·  Rectal Diseases (13)  ·  Colonic Diseases (12)  ·  Pancreatic Diseases (12)  ·  Endocrine Gland Neoplasms (11)  ·  Endocrine System Diseases (11)  ·  Neoplasms by Histologic Type (11)  ·  Neoplasms, Glandular and Epithelial (10)

Interventions

Gemcitabine (4)  ·  Bevacizumab (3)  ·  Capecitabine (3)  ·  Irinotecan (3)  ·  Oxaliplatin (3)  ·  S 1 (combination) (3)  ·  trifluridine tipiracil drug combination (3)  ·  Drug Therapy (2)  ·  Fluorouracil (2)  ·  Leucovorin (2)  ·  Radiotherapy (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  ABTL0812 (1)  ·  Albumin-Bound Paclitaxel (1)  ·  Anticoagulants (1)

Sponsors

Hokkaido Gastrointestinal Cancer Study Group (3)  ·  The Clatterbridge Cancer Centre NHS Foundation Trust (2)  ·  AIM ImmunoTech Inc. (1)  ·  ARCA Biopharma, Inc. (1)  ·  Ability Pharmaceuticals SL (1)  ·  CMED HIFU Development Corporation (1)  ·  Calibr, a division of Scripps Research (1)  ·  Cancer Research UK (1)  ·  Case Comprehensive Cancer Center (1)  ·  Flatley Discovery Lab LLC (1)  ·  Fudan University (1)  ·  Gruppo Oncologico del Nord-Ovest (1)  ·  HRYZ Biotech Co. (1)  ·  Healeon Medical Inc (1)  ·  Holy Stone Healthcare Co., Ltd (1)

Countries

United States (19)  ·  China (9)  ·  France (4)  ·  United Kingdom (4)  ·  Japan (3)  ·  Italy (2)  ·  Spain (2)  ·  Canada (1)  ·  Germany (1)  ·  Malaysia (1)  ·  Netherlands (1)  ·  Norway (1)  ·  Thailand (1)

Top investigators

Masahiro Asaka, MD, PhD (2)  ·  Alan Thomson, MD, Prof. (1)  ·  Andrew Poklepovic, MD (1)  ·  Ardaman S. Shergill, MD (1)  ·  Carri Glide-Hurst, PhD, DABR, FAAPM (1)  ·  Chen Ming, MD (1)  ·  Daniel H Palmer, BSC, PhD (1)  ·  Daniel Lin, MD (1)  ·  Daniel Palmer, PhD, MD (1)  ·  David R Strayer, MD (1)  ·  Fiona Blackhall, Prof (1)  ·  Glenn C Terry, MD (1)  ·  Guus Bol, Dr. (1)  ·  Harald Hoensch, Professor (1)

Results publications

PMID 20510306, PMID 21054494, PMID 24006012, PMID 24635869, PMID 28069018, PMID 29800971, PMID 31182448, PMID 32557715, PMID 33593311, PMID 34482636, PMID 36331676

NIH funding

2009 (1), 2017 (1), 2019 (1), R01HL153720 (1)